Bohuslav Melichar

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

Enrollment Status: Active_not_recruiting

Publish Date: February 04, 2025

Intervention Type: Drug

Study Drugs: Selpercatinib, Cabozantinib, Vandetanib

Study Phase: Phase 3

A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC

Enrollment Status: Completed

Publish Date: January 31, 2025

Intervention Type: Drug

Study Drugs: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin

Study Phase: Phase 3

LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Enrollment Status: Active_not_recruiting

Publish Date: January 30, 2025

Intervention Type: Drug

Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab

Study Phase: Phase 3

A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

Enrollment Status: Active_not_recruiting

Publish Date: January 20, 2025

Intervention Type: Drug

Study Phase: Phase 3

HEPANOVA: a Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC)

Enrollment Status: Completed

Publish Date: November 14, 2024

Intervention Type: Device, Drug

Study Drug: Sorafenib

Study Phase: Phase 2

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma

Enrollment Status: Completed

Publish Date: October 31, 2024

Intervention Type: Drug, Device

Study Drugs: Gemcitabine, Nab-paclitaxel

Study Phase: Phase 3

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Enrollment Status: Completed

Publish Date: October 26, 2024

Intervention Type: Drug

Study Drugs: Cisplatin, Capecitabine, Paclitaxel, Fluorouracil (5-FU), Oxaliplatin, Tislelizumab

Study Phase: Phase 3

Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma

Enrollment Status: Completed

Publish Date: September 23, 2024

Intervention Type: Radiation, Drug

Study Drug: Nivolumab

Study Phase: Phase 1/Phase 2

A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Enrollment Status: Active_not_recruiting

Publish Date: August 16, 2024

Intervention Type: Drug

Study Drugs: Niraparib, Dostarlimab

Study Phase: Phase 3

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

Enrollment Status: Active_not_recruiting

Publish Date: August 09, 2024

Intervention Type: Drug

Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed

Study Phase: Phase 3

ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer

Enrollment Status: Completed

Publish Date: March 29, 2024

Intervention Type: Device, Drug

Study Drug: Paclitaxel

Study Phase: Phase 3

A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer

Enrollment Status: Terminated

Publish Date: January 16, 2024

Intervention Type: Drug, Radiation

Study Drugs: M7824, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin

Study Phase: Phase 2

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

Enrollment Status: Completed

Publish Date: August 14, 2023

Intervention Type: Drug

Study Drugs: tucatinib, capecitabine, trastuzumab

Study Phase: Phase 2

A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer

Enrollment Status: Completed

Publish Date: July 25, 2023

Intervention Type: Drug

Study Drug: Tisotumab Vedotin

Study Phase: Phase 2

A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

Enrollment Status: Completed

Publish Date: May 06, 2023

Intervention Type: Drug

Study Drugs: EndoTAG-1, Gemcitabine

Study Phase: Phase 3

'An Open Label, Multicentre, Phase I Study to Evaluate the Impact of Moderate and Severe Hepatic Impairments on the Pharmacokinetics and Safety of Encorafenib in Combination With Binimetinib in Adult Patients With Unresectable or Metastatic BRAF V600-mutant Solid Tumors'.

Enrollment Status: Withdrawn

Publish Date: February 21, 2023

Intervention Type: Drug

Study Drug: Encorafenib+Binimetinib

Study Phase: Phase 1

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Enrollment Status: Completed

Publish Date: November 23, 2022

Intervention Type: Drug, Biological

Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine

Study Phase: Phase 3

A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

Enrollment Status: Terminated

Publish Date: November 08, 2022

Intervention Type: Drug

Study Drugs: Ipilimumab, IMO-2125

Study Phase: Phase 3

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Enrollment Status: Completed

Publish Date: October 06, 2022

Intervention Type: Drug

Study Drugs: Avapritinib, Regorafenib

Study Phase: Phase 3

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

Enrollment Status: Terminated

Publish Date: July 30, 2021

Intervention Type: Drug

Study Drugs: Tesetaxel and Capecitabine, Capecitabine

Study Phase: Phase 3

A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma

Enrollment Status: Unknown

Publish Date: January 24, 2017

Intervention Type: Drug

Study Drug: Sodium Cridanimod

Study Phase: Phase 2

Overview

Locations

Clinical Research

21 Clinical Trials

307 Total Publications

Areas of Expertise